Cardiff Oncology (CRDF) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Cardiff Oncology (CRDF) over the past year, losing 32.4% versus a loss of 54.6%. Cardiff Oncology is the larger company by market cap ($84.0 million vs $74.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | OKYO |
|---|---|---|
| Share price | $1.08 | $1.42 |
| Market cap | $84.02M | $74.52M |
| 1-day change | +1.89% | +2.16% |
| YTD return | -61.57% | -31.40% |
| 1-year return | -54.62% | -32.38% |
| 5-year return | -83.13% | — |
| EPS (TTM) | $-0.60 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $3.20 |
| 52-week low | $0.76 | $1.27 |
| Distance from 52-week high | -67.37% | -55.63% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +437.96% | +486.62% |
| Average volume | 1.04M | 94.38K |
| Shares outstanding | 77.80M | 52.48M |
| Employees | 30 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed CRDF by 22.2 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
CRDF vs OKYO FAQ
Which is bigger, Cardiff Oncology or OKYO Pharma?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $84.02M compared with $74.52M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, CRDF or OKYO?
OKYO returned -32.38% over the past 12 months, compared with -54.62% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.